Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.590
+0.040 (1.13%)
At close: Jun 26, 2026, 4:00 PM EDT
3.630
+0.040 (1.11%)
After-hours: Jun 26, 2026, 6:42 PM EDT
Voyager Therapeutics Employees
Voyager Therapeutics had 141 employees as of December 31, 2025. The number of employees decreased by 31 or -18.02% compared to the previous year.
Employees
141
Change (1Y)
-31
Growth (1Y)
-18.02%
Revenue / Employee
$258,823
Profits / Employee
-$827,213
Market Cap
216.91M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 146 |
| Tonix Pharmaceuticals Holding | 142 |
| Alector | 103 |
| Immunic | 95 |
| Keros Therapeutics | 87 |
| Camp4 Therapeutics | 48 |
| Whitehawk Therapeutics | 29 |
| Q32 Bio | 22 |
VYGR News
- 13 days ago - Voyager Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 16 days ago - Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference - GlobeNewsWire
- 18 days ago - Voyager Therapeutics Transcript: AGM 2026 - Transcripts
- 26 days ago - Voyager Therapeutics announces FDA clearance for VY1706 IND application - TheFly
- 26 days ago - Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease - GlobeNewsWire
- 6 weeks ago - Voyager Therapeutics presents GLP for toxicology data for VY1706 - TheFly
- 6 weeks ago - Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 - GlobeNewsWire
- 7 weeks ago - Voyager Therapeutics reports Q1 EPS (47c), consensus (53c) - TheFly